SAN DIEGO, Oct. 24, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce the Company’s scheduled presentations during the upcoming Transcatheter Cardiovascular Therapeutics (“TCT”) Conference, being held October 29th through November 2nd in Washington, DC.
REVA has been selected to present data from the FANTOM II clinical trial during the First Report Investigations, which are being conducted in the Main Arena II on Monday, October 31st. Dr. Alexandre Abizaid, co-principal investigator for the trial and Director of Invasive Cardiology at Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, will present the data.
The complete schedule of REVA’s presentations is as follows:
|Monday October 31, 2016|
Room 103B, Level 1
|Oral Abstract Session: New Bioresorbable Scaffolds|
FANTOM II: Six-month Follow-up by OCT
Presented by Jo Simonsen
Main Arena II
|Session: First Report Investigations 2|
FANTOM II: Final Six-month Results from Cohorts A & B
Presented by Dr. Alexandre Abizaid
Room 151, Level 1
|Session: The Vast BRS World and Beyond|
FANTOM II: Novel Design Attributes and 6-month Results
Presented by Dr. Jose de Ribamar Costa Jr.
|Tuesday November 1, 2016|
|Session: Making the Case for a Fully Bioresorbable Future|
Presented by Dr. Alexandre Abizaid
Following the release of results from the FANTOM II trial, REVA will hold an institutional investor briefing to review the clinical data with members of the investment community. The meeting will be held on Monday, October 31, 2016 at 3:00 p.m. at the Embassy Suites DC Convention Center Hotel, located at 900 10th Street, NW, Washington, DC.
The clinical data presented at the conference will be available in the Investor Relations section of REVA’s website at www.revamedical.com following the presentations. The clinical results will also be lodged with the Australian Securities Exchange and filed with the US Securities and Exchange Commission.
REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable scaffolds, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s Fantom® scaffold has been designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require regulatory approval before it can commercialize Fantom or any other product.
This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to obtain regulatory approvals, timely and successfully complete our clinical trials, protect our intellectual property position, commercialize our products if and when approved, develop and commercialize new products, recruit and retain our key personnel, and estimates regarding our capital requirements and financial performance. You should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the “SEC”) on March 10, 2016, and as may be updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
|Investor & Media Enquiries:||Investor Enquiries:||Media Enquiries:|
|REVA Medical, Inc.||Inteq Limited||Buchan Consulting|
|Cheryl Liberatore||Kim Jacobs||Rebecca Wilson|
|Director, Communications||+61 438 217 279||+61 3 9866 4722|
|+1 858-966-3045||Andrew Cohen|
|+61 408 333 452|
Source: REVA Medical Inc